人急性非B非T淋巴细胞白血病细胞Reh
BLUEFBIO™ Product Sheet
|
细胞名称 |
人急性非B非T淋巴细胞白血病细胞Reh |
|
|
|
货物编码 |
BFN60806597 |
||
|
产品规格 |
T25培养瓶x1 |
1.5ml冻存管x2 |
|
|
细胞数量 |
1x10^6 |
1x10^6 |
|
|
保存温度 |
37℃ |
-198℃ |
|
|
运输方式 |
常温保温运输 |
干冰运输 |
|
|
安全等级 |
1 |
||
|
用途限制 |
仅供科研 2类 |
||
|
培养体系 |
DMEM高糖+10%FBS+1%双抗 |
||
|
培养温度 |
37℃ |
二氧化碳浓度 |
5% |
|
简介 |
人急性非B非T淋巴细胞白血病细胞Reh取自15岁女性供体，该细胞源于ATCC |
||
|
序列突变 |
/ |
||
|
注释 |
Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: LL-100 blood cancer cell line panel. Part of: MD Anderson Cell Lines Project. Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ). Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger). Omics: Array-based CGH. Omics: Deep antibody staining analysis. Omics: Deep exome analysis. Omics: Deep quantitative phosphoproteome analysis. Omics: Deep quantitative proteome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: Protein expression by reverse-phase protein arrays. Omics: shRNA library screening. Omics: SNP array analysis. Omics: Transcriptome analysis. Derived from sampling site: Peripheral blood. |
||
|
STR信息 |
Amelogenin X CSF1PO 10,11,12 (AddexBio; ATCC; PubMed=25877200) 12,13 (CLS; Cosmic-CLP; DSMZ) D3S1358 18 D5S818 11,13 (AddexBio; ATCC; PubMed=25877200) 11,12,13 (CLS) 11,12 (Cosmic-CLP; DSMZ) D7S820 9,12 (AddexBio; ATCC; Cosmic-CLP; DSMZ; PubMed=25877200) 9,10,12,13 (CLS) D8S1179 13,14,16,17 (CLS) 13,15 (PubMed=25877200) D13S317 11,13 (AddexBio; ATCC; PubMed=25877200) 11,12,13 (CLS) 11,14 (Cosmic-CLP) 10,11,14 (DSMZ) D16S539 9 (AddexBio; ATCC; PubMed=25877200) 9,10,12,13 (CLS) 9,13 (Cosmic-CLP; DSMZ) D18S51 10,11,14 (CLS) 10,14 (PubMed=25877200) D21S11 28,29,30,31 (CLS) 28,30 (PubMed=25877200) FGA 22,23,24 (CLS) 22,23 (PubMed=25877200) Penta D 9,12 (CLS) 9,11 (PubMed=25877200) Penta E 10,11 (CLS) 7,11 (PubMed=25877200) TH01 7 (AddexBio; ATCC; CLS; PubMed=25877200) 7,9 (Cosmic-CLP; DSMZ) TPOX 8 vWA 14,15 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200) 14,15,16 (CLS; DSMZ) |
||
|
参考文献 |
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31160637; DOI=10.1038/s41598-019-44491-x Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G. The LL-100 panel: 100 cell lines for blood cancer studies. Sci. Rep. 9:8218-8218(2019)
PubMed=31978347; DOI=10.1016/j.cell.2019.12.023 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402(2020) |
||
